Literature DB >> 30226585

B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients.

Monika Pizon1, Dorothea Sonja Schott1, Ulrich Pachmann1, Katharina Pachmann1.   

Abstract

Circulating epithelial tumor cells (CETCs) in peripheral blood are a prerequisite for the development of metastases. B7-H3 is an important immune checkpoint member of the B7 family and inhibits T-cell mediated antitumor immunity. Its expression is associated with a negative prognosis and a poor clinical outcome. Based on the clinical success of inhibitory immune checkpoint blockade, monoclonal antibodies (mAbs) against B7-H3 appear to be a promising therapeutic strategy. The proliferation biomarker, Ki-67, is used as a prognostic factor for breast cancer and reflects the proliferative potential of the tumor. In order to better understand the role of B7-H3 and Ki-67 in cancer development, in this study, we used a real-time biopsy for determining both biomarkers on CETCs in breast cancer patients. Blood from 50 patients suffering from breast cancer was analyzed for CETCs and the expression of B7-H3 and Ki-67 using the maintrac® method. B7-H3 expression on CETCs was found in 82% of the patients. The frequency of B7-H3- and Ki-67‑positive CETCs was significantly higher in patients who had received radiation therapy compared to patients who had not received irradiation. B7-H3‑positive CETCs seemed to be more aggressive as the percentage of B7-H3‑positive CETCs correlated with the percentage of cells positive for the proliferation marker, Ki-67 (r=0.72 P<0.001). A significant association between the Ki-67 and B7-H3 expression level on the CETCs and nodal status was observed. On the whole, the findings of this study indicate that breast cancer patients have detectable CETCs with a high frequency of B7-H3 expression regardless of the stage of the disease. B7-H3 seems to be an important factor in immune evasion and may thus be a promising target for anticancer therapies. Radiation may lead to an upregulation of B7-H3 expression on CETCs, which could be a possible mechanism of acquired radio-resistance.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30226585     DOI: 10.3892/ijo.2018.4551

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  B7 homolog 3 induces lung metastasis of breast cancer through Raf/MEK/ERK axis.

Authors:  Shuai Wang; Xinyan Zhang; Houfa Ning; Senyi Dong; Guangzhi Wang; Ruimei Sun
Journal:  Breast Cancer Res Treat       Date:  2022-03-21       Impact factor: 4.872

2.  Prognostic value of immune checkpoint molecules in breast cancer.

Authors:  Feng Chen; Dong Liu; Jun Fang; Feiying Gu; Zhigang Chen; Yuezhen Wang
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

3.  Increased expression of FAK isoforms as potential cancer biomarkers in ovarian cancer.

Authors:  Manuel Nolasco-Quiroga; Marisol Rosas-Díaz; José Moreno; Ricardo Godínez-Aguilar; María José López-Ibarra; Patricia Piña-Sánchez; Isabel Alvarado-Cabrero; Gerardo Vázquez-Gómez; Leticia Rocha-Zavaleta; Diego Arenas-Aranda; Fabio Salamanca-Gómez
Journal:  Oncol Lett       Date:  2019-03-15       Impact factor: 2.967

Review 4.  The complexity of tumour angiogenesis based on recently described molecules.

Authors:  Weronika Wiśniewska; Michał Kopka; Karolina Siemiątkowska; Marta Magdalena Fudalej; Aleksandra Sobiborowicz; Anna Maria Badowska-Kozakiewicz
Journal:  Contemp Oncol (Pozn)       Date:  2021-04-15

5.  Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T cell infiltration.

Authors:  Okan Avci; Eyyup Çavdar; Yakup İriağaç; Kubilay Karaboyun; Aliye Çelikkol; Tuğba İlkem Kurtoğlu Özçağlayan; Meltem Öznur; Sibel Özkan Gürdal; Erdoğan Selçuk Şeber
Journal:  Contemp Oncol (Pozn)       Date:  2022-02-11

6.  Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry.

Authors:  Mei Wu; Qi Sun; Chao-Hua Mo; Jin-Shu Pang; Jia-Yin Hou; Ling-Ling Pang; Hui-Ping Lu; Yi-Wu Dang; Su-Jie Fang; Deng Tang; Gang Chen; Zhen-Bo Feng
Journal:  Oncol Rep       Date:  2019-05-03       Impact factor: 3.906

7.  Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.

Authors:  Andrea Nicolini; Paola Ferrari; Riccardo Morganti; Angelo Carpi
Journal:  Int J Mol Sci       Date:  2019-11-28       Impact factor: 5.923

8.  B7-H3 regulates KIF15-activated ERK1/2 pathway and contributes to radioresistance in colorectal cancer.

Authors:  Yanchao Ma; Shenghua Zhan; Huimin Lu; Ruoqin Wang; Yunyun Xu; Guangbo Zhang; Lei Cao; Tongguo Shi; Xueguang Zhang; Weichang Chen
Journal:  Cell Death Dis       Date:  2020-10-03       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.